Sterling Pharma Solutions experiences record US growth

The CDMO's US sales have increased from £15.5 million to £41 million since 2016.

The increase in sales forms part of the company’s growth strategy, which is focused on key markets including the US, UK, Japan and Europe. Sterling’s US sales now make up 68% of its business, having increased from £15.5 million to £41 million since 2016.

Kevin Cook, CEO of Sterling Pharma Solutions said: “The US is a major market for Sterling due to the recent growth in the emerging pharma sector and significant presence of large pharma companies. As such, we’ve spent time investing in our presence and expanding our customer base in the country.

“We recently completed a successful general inspection audit with the FDA in February 2018 with no 483 observations. This is another significant milestone for the business and allows us to continue servicing our customers with the highest quality standards. We’re committed to continuing to grow our presence in the US and maintaining our growth trajectory.”

Sterling Pharma Solutions is the UK’s largest provider of API development and manufacturing services to the pharmaceutical industry and specialises in handling hazardous chemistries. Its diverse portfolio now includes more than 60 products with no single product representing over 15% of its total sales.